Clinical Trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-04; most recent amendment 2025-10-27.
Status change: Not Yet Recruiting → Recruiting 2025-01-13
Trial Details
NCT Number NCT06724640
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 168 participants
Start Date 2024-12-16
Primary Completion 2028-08-16 (estimated)
Study Completion 2028-08-16 (estimated)
Updated on ClinicalTrials.gov 2025-10-29